| answer text |
<p>The 2015 Comprehensive Spending Review made a commitment to invest up to £300 million
per year by 2020/21. The published financial profile agreed for the NHS England Cancer
Programme over the four years to 2020/21 was:</p><p> </p><table><tbody><tr><td><p>2017/18</p></td><td><p>2018/19</p></td><td><p>2019/20</p></td><td><p>2020/21</p></td></tr><tr><td><p>£123
million</p></td><td><p>£140 million</p></td><td><p>£154 million</p></td><td><p>£190
million</p></td></tr></tbody></table><p> </p><p>This is being invested in earlier
diagnosis and personalised care, including additional staff capacity and equipment.
In addition, £130 million has been invested to modernise radiotherapy equipment. Funding
has been allocated for over 80 new or upgraded linear accelerators across the country
since October 2016.</p>
|
 |
